Glaxo to benefit from likely revision in formulation price - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Feb 9, 2000 - Glaxo to benefit from likely revision in formulation price

Glaxo to benefit from likely revision in formulation price

Feb 9, 2000

The National Pharmaceutical Pricing Authority (NPPA) is likely to revise (upwards) the prices of betamethasone (‘Betnovate’) formulations. The decision, if it materialises, would come into force within six to eight weeks. Glaxo India is a 51% subsidiary of the £ 8 billion Glaxo Plc. UK which has blockbusters like Zantac and Zovirax to its credit. It has two other group companies Burroughs Wellcome India and Biddle Sawyer. The company has almost 60% of its revenues accruing from products, which are under price control and betamethasone formulations account for a fourth of such revenues.

The NPPA was set up in 1997 as the official body to administer the Drug Price Control Order (DPCO). It announces price revisions almost every month. Most of the times the recommendations do affect the multinational pharmaceutical companies since they are the ones which have a relatively higher proportion (anywhere between 45-60%) of the revenues accruing from products under price control.

Glaxo would be among the largest beneficiaries of an upward revision in Betamethasone based formulations since these account for around 15% of its turnover. The companies Betnovate-C and Betnovate-N brands enjoy a market share of 35% and 45% respectively and both have grown at a rate of 10% in recent times much higher than industry rates of 7-8%.

This makes it apparent that the company’s profitability is artificially depressed and depends on the whims and fancies of the NPPA. As and when the DPCO (which has 76 drugs under its ambit) is liberalised (around 15 drugs are supposed to be under price control post liberalisation) the profitability of Glaxo would improve substantially.

Market View:
Most analysts have rated Glaxo as a buy for three reasons. Firstly, on account of the parent’s product pipeline post its merger with Smithkline. Second the fact that Glaxo India has not followed minority shareholder unfriendly policies such as setting up a 100% subsidiary or payment of hefty royalties to the parent. And third, the company has substantial cash in its balance sheet that can be used for future acquisition as the Indian pharmaceutical sector witnesses a consolidation.

Equitymaster requests your view! Post a comment on "Glaxo to benefit from likely revision in formulation price". Click here!


More Views on News

GSK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of GSK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 1, 2021 (Close)


  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks